

Giada Sebastiani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8452538/publications.pdf>

Version: 2024-02-01

120
papers

6,387
citations

70961

41
h-index

69108

77
g-index

121
all docs

121
docs citations

121
times ranked

7510
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , 2017, 65, 1557-1565.	3.6	1,294
2	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1611-1625.e12.	0.6	575
3	Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2006, 44, 686-693.	1.8	247
4	Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. <i>World Journal of Gastroenterology</i> , 2006, 12, 3682.	1.4	220
5	Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2010, 52, 191-198.	1.8	188
6	Chronic hepatitis C and liver fibrosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 11033.	1.4	178
7	Liver fibrosis: Review of current imaging and MRI quantification techniques. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1276-1295.	1.9	163
8	SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2009, 49, 1821-1827.	3.6	151
9	Limitations of non-invasive tests for assessment of liver fibrosis. <i>JHEP Reports</i> , 2020, 2, 100067.	2.6	133
10	Cloning and Characterization of the Murine Toll-like Receptor 5 (Tlr5) Gene: Sequence and mRNA Expression Studies in Salmonella-Susceptible MOLF/Ei Mice. <i>Genomics</i> , 2000, 64, 230-240.	1.3	125
11	Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, large-scale study. <i>Journal of Hepatology</i> , 2010, 53, 630-638.	1.8	123
12	Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2007, 13, 525.	1.4	123
13	2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. <i>HIV Medicine</i> , 2020, 21, 617-624.	1.0	115
14	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 878-885.	1.8	113
15	The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1202-1216.	1.9	111
16	Pharmacological Targeting of the Hepcidin/Ferroportin Axis. <i>Frontiers in Pharmacology</i> , 2016, 7, 160.	1.6	100
17	A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. <i>Hepatology</i> , 2009, 50, 1038-1044.	3.6	91
18	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	2.4	90

#	ARTICLE	IF	CITATIONS
19	Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1937-1944.	0.9	83
20	Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. <i>Aids</i> , 2016, 30, 2635-2643.	1.0	78
21	Mapping of Genetic Modulators of Natural Resistance to Infection with <i>Salmonella typhimurium</i> Wild-Derived Mice. <i>Genomics</i> , 1998, 47, 180-186.	1.3	72
22	Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis. <i>European Radiology</i> , 2019, 29, 6477-6488.	2.3	72
23	Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. <i>Journal of Hepatology</i> , 2017, 67, 801-808.	1.8	70
24	Non-invasive assessment of liver fibrosis in chronic liver diseases: Implementation in clinical practice and decisional algorithms. <i>World Journal of Gastroenterology</i> , 2009, 15, 2190.	1.4	69
25	Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. <i>World Journal of Gastroenterology</i> , 2016, 22, 7727.	1.4	65
26	Systematic review: Preventive and therapeutic applications of metformin in liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 1652.	0.8	63
27	Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw531.	2.9	60
28	Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 124-133.	0.9	60
29	Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. <i>PLoS ONE</i> , 2015, 10, e0128774.	1.1	59
30	An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards. <i>Journal of Hepatology</i> , 2015, 62, 807-815.	1.8	54
31	Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2006, 13, 199-205.	1.0	51
32	Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: A systematic review. <i>International Journal of Drug Policy</i> , 2018, 57, 95-103.	1.6	50
33	Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0185192.	1.1	50
34	Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. <i>Journal of Viral Hepatitis</i> , 2008, 15, 212-218.	1.0	49
35	Conditional disruption of mouse HFE2 gene: Maintenance of systemic iron homeostasis requires hepatic but not skeletal muscle hemojuvelin. <i>Hepatology</i> , 2011, 54, 1800-1807.	3.6	49
36	Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. <i>Journal of Hepatology</i> , 2006, 44, 83-87.	1.8	48

#	ARTICLE	IF	CITATIONS
37	Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice. <i>Metallomics</i> , 2011, 3, 971.	1.0	48
38	How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 18-32.	1.0	46
39	Natural history of initially mild chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2004, 36, 646-654.	0.4	45
40	Differences in activation of mouse hepcidin by dietary iron and parenterally administered iron dextran: compartmentalization is critical for iron sensing. <i>Journal of Molecular Medicine</i> , 2013, 91, 95-102.	1.7	44
41	Physicians' Practices for Diagnosing Liver Fibrosis in Chronic Liver Diseases: A Nationwide, Canadian Survey. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 23-30.	0.8	42
42	Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study. <i>CMAJ Open</i> , 2020, 8, E429-E436.	1.1	42
43	Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfecting with hepatitis D virus. <i>Journal of Viral Hepatitis</i> , 2012, 19, e170-6.	1.0	41
44	Comparison of three algorithms of noninvasive markers of fibrosis in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 92-104.	1.9	41
45	HFE gene in primary and secondary hepatic iron overload. <i>World Journal of Gastroenterology</i> , 2007, 13, 4673.	1.4	38
46	Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. <i>PLoS ONE</i> , 2018, 13, e0191985.	1.1	33
47	Iron-Dependent Regulation of Hepcidin in HJV ^{-/-} Mice: Evidence That Hemojuvelin Is Dispensable for Sensing Body Iron Levels. <i>PLoS ONE</i> , 2014, 9, e85530.	1.1	32
48	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	1.0	28
49	Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, e694-e701.	2.9	27
50	Serum fibrosis biomarkers predict death and graft loss in liver transplantation recipients. <i>Liver Transplantation</i> , 2015, 21, 1383-1394.	1.3	26
51	Incidence and Predictors of Hepatic Steatosis and Fibrosis by Serum Biomarkers in a Large Cohort of Human Immunodeficiency Virus Mono-Infected Patients. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv015.	0.4	25
52	Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. <i>Aids</i> , 2020, 34, 237-244.	1.0	25
53	Accelerated CCl ₄ -Induced Liver Fibrosis in HJV ^{-/-} Mice, Associated with an Oxidative Burst and Precocious Profibrogenic Gene Expression. <i>PLoS ONE</i> , 2011, 6, e25138.	1.1	24
54	Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy. <i>Antiviral Research</i> , 2012, 96, 422-429.	1.9	24

#	ARTICLE	IF	CITATIONS
55	Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 13-32.	1.4	23
56	NASH in HIV. <i>Current HIV/AIDS Reports</i> , 2020, 17, 601-614.	1.1	23
57	Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3017-3025.e6.	2.4	21
58	AISF position paper on liver transplantation and pregnancy. <i>Digestive and Liver Disease</i> , 2016, 48, 860-868.	0.4	20
59	Clinical significance of elevated liver transaminases in HIV-infected patients. <i>Aids</i> , 2019, 33, 1267-1282.	1.0	19
60	Quantitative ultrasound, elastography, and machine learning for assessment of steatosis, inflammation, and fibrosis in chronic liver disease. <i>PLoS ONE</i> , 2022, 17, e0262291.	1.1	19
61	Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. <i>World Journal of Gastroenterology</i> , 2020, 26, 7046-7060.	1.4	18
62	Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac003.	0.4	18
63	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 604-615.	1.9	18
64	Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study. <i>The Lancet Digital Health</i> , 2022, 4, e188-e199.	5.9	18
65	Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage to care strategies for people released from prison: Findings from a systematic review. <i>Journal of Viral Hepatitis</i> , 2020, 27, 205-220.	1.0	17
66	Intravoxel incoherent motion diffusion-weighted MRI for the characterization of inflammation in chronic liver disease. <i>European Radiology</i> , 2021, 31, 1347-1358.	2.3	17
67	New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. <i>Hepatology</i> , 2020, 71, 1831-1844.	3.6	16
68	Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 942-950.	1.0	16
69	Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening. <i>Hepatology</i> , 2012, 56, 455-463.	3.6	15
70	The hepatitis C virus cascade of care in a Quebec provincial prison: a retrospective cohort study. <i>CMAJ Open</i> , 2019, 7, E674-E679.	1.1	14
71	Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis. <i>Clinical Infectious Diseases</i> , 2019, 69, 1422-1430.	2.9	14
72	Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Mono-infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e2184-e2193.	2.9	14

#	ARTICLE	IF	CITATIONS
73	Occult cirrhosis diagnosed by transient elastography is a frequent and under-monitored clinical entity. <i>Liver International</i> , 2015, 35, 2285-2293.	1.9	13
74	Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients. <i>HIV Medicine</i> , 2020, 21, 96-108.	1.0	12
75	Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 222, 787-797.	1.9	12
76	Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: A systematic review and meta-analysis. <i>JGH Open</i> , 2021, 5, 434-445.	0.7	12
77	Transient elastography is an unreliable marker of liver fibrosis in patients with portal vein thrombosis. <i>Hepatology</i> , 2018, 68, 783-785.	3.6	11
78	Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. <i>Clinical Infectious Diseases</i> , 2020, 71, 2810-2817.	2.9	11
79	Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. <i>Aids</i> , 2020, 34, 1915-1921.	1.0	11
80	Fatty liver in H63D homozygotes with hyperferritinemia. <i>World Journal of Gastroenterology</i> , 2006, 12, 1788.	1.4	9
81	Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond. <i>World Journal of Gastroenterology</i> , 2021, 27, 1959-1972.	1.4	7
82	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022, 5, 61-90.	0.3	7
83	Serum biomarkers for the non-invasive diagnosis of liver fibrosis: the importance of being validated. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 595-7.	1.4	6
84	Incidence and Predictors of Advanced Liver Fibrosis by a Validated Serum Biomarker in Liver Transplant Recipients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-8.	0.8	6
85	MRI cine-tagging of cardiac-induced motion for noninvasive staging of liver fibrosis. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1570-1580.	1.9	6
86	Distinct Hepatitis B and HIV co-infected populations in Canada. <i>Journal of Viral Hepatitis</i> , 2021, 28, 517-527.	1.0	6
87	Implementing non-invasive markers for liver fibrosis in clinical practice. <i>Journal of Hepatology</i> , 2008, 48, 880-881.	1.8	5
88	Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107978.	1.2	5
89	HIV, Elevated Transaminases, Fatty Liver: The Perfect Storm?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e23-e25.	0.9	4
90	Inference about time-dependent prognostic accuracy measures in the presence of competing risks. <i>BMC Medical Research Methodology</i> , 2020, 20, 219.	1.4	4

#	ARTICLE	IF	CITATIONS
91	A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048.	1.9	4
92	Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-positive patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1077-1082.	1.9	3
93	Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1385-1395.	0.8	3
94	A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4046-4057.	1.1	3
95	FIB-4 Improves LSM-Based Prediction of Complications in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2396-2398.e3.	2.4	3
96	Sarcopenic obesity at the crossroad of pathogenesis of cardiometabolic diseases. <i>Atherosclerosis</i> , 2021, 335, 84-86.	0.4	3
97	“Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV”, <i>HIV Medicine</i> , 2022, 23, 911-921.	1.0	3
98	Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway. <i>Lancet HIV</i> , 2022, 9, S4.	2.1	3
99	Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study. <i>World Journal of Hepatology</i> , 2021, 13, 2179-2191.	0.8	3
100	Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. <i>Journal of Viral Hepatitis</i> , 2008, 15, 474-474.	1.0	2
101	Letters to the Editor. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 219-220.	0.8	2
102	Serpinb3 is Overexpressed in the Liver in Presence of Iron Overload. <i>Journal of Investigative Medicine</i> , 2018, 66, 32-38.	0.7	2
103	A190 REGRESSION OF LIVER FIBROSIS AFTER SUCCESSFUL ALL ORAL ANTIVIRAL THERAPY IN HCV CIRRHOSIS: A PILOT STUDY EMPLOYING TRANSIENT ELASTOGRAPHY AND CONTROLLED ATTENUATION PARAMETER (CAP). <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 331-331.	0.1	2
104	Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 994-1009.	1.1	2
105	Letters to the Editor. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 221-222.	0.8	1
106	Hepatic steatosis, hepatitis C, and human immunodeficiency viruses: A complex interplay. <i>Hepatology</i> , 2017, 66, 673-674.	3.6	1
107	A199 SCREENING FOR NONALCOHOLIC FATTY LIVER DISEASE BY TRANSIENT ELASTOGRAPHY WITH CONTROLLED ATTENUATION PARAMETER IN UNSELECTED PATIENTS WITH INFLAMMATORY BOWEL DISEASE. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 347-348.	0.1	1
108	Reply to “Transient Elastography in IBD Patients”, <i>Inflammatory Bowel Diseases</i> , 2019, 25, e95-e95.	0.9	1

#	ARTICLE	IF	CITATIONS
109	Nonalcoholic Fatty Liver Disease in Human Immunodeficiency Virus: The (Not So) New Kid on the Block?. <i>Clinical Infectious Diseases</i> , 2020, 71, 243-244.	2.9	1
110	Optimizing patients with non-alcoholic fatty liver disease pre-transplant. <i>Canadian Liver Journal</i> , 2020, 3, 237-250.	0.3	1
111	Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 807-820.	0.5	1
112	The 8th Canadian Symposium on Hepatitis C virus: "Improving diagnosis and linkage to care". <i>Canadian Liver Journal</i> , 2020, 3, 3-14.	0.3	1
113	Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 282.	1.1	1
114	Non-invasive algorithms for liver fibrosis: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 311-313.	1.9	0
115	Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , 2018, 69, 1203-1204.	1.8	0
116	Reply to Giannini et al. <i>Clinical Infectious Diseases</i> , 2021, 72, 1863-1864.	2.9	0
117	Acute liver failure in ruptured sinus of Valsalva aneurysm. <i>Canadian Liver Journal</i> , 0, , e20210012.	0.3	0
118	Fibrosis Assessment via Liver Stiffness Measurements: How Many Patients Are Spared from a Liver Biopsy?. , 2020, , 563-588.		0
119	A110 FEASIBILITY OF EUS-GUIDED PORTAL PRESSURE GRADIENT MEASUREMENT WITHOUT DEEP SEDATION: A PATH TO ACCURATE PORTAL PRESSURE DETERMINATION. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 127-128.	0.1	0
120	A220 THE IMPACT OF DIABETES AND AGE ON PERFORMANCE OF NON-INVASIVE SERUM-BASED TESTS FOR PREDICTION OF ADVANCED FIBROSIS IN BIOPSY-PROVEN NAFLD. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 109-110.	0.1	0